GLP-1 Coverage Guide is a private website. We are not Medicare, the Centers for Medicare & Medicaid Services (CMS), or any government agency, and we are not affiliated with or endorsed by them.
Text size:

Zepbound under the Bridge — and the KwikPen rule you must know

Short answer: Zepbound — Eli Lilly's weekly tirzepatide injection — is covered at $50/month under the Medicare GLP-1 Bridge, but only in its KwikPen form. Vials and single-dose pens will not process under the program. This is the single most common surprise at the pharmacy counter, and it's avoidable if your prescription says KwikPen from the start.

Program facts last verified against CMS: July 21, 2026

Only the Zepbound KwikPen is covered at $50. Single-dose pens and vials are not covered under the program.✓KwikPen — COVERED✗Single-dose pen — NOT covered✗Vial — NOT coveredAsk your doctor to write “Zepbound KwikPen” — and check the box before leaving the pharmacy.
The #1 pharmacy-counter surprise, avoided: only the KwikPen form of Zepbound processes at $50 under the program.

What Zepbound is

Zepbound is a once-weekly injection of tirzepatide, which activates two hormone receptors (GLP-1 and GIP). In trials it produced the largest average weight loss of any approved medication in this class — around 20% of body weight at higher doses — and it also holds an FDA approval for moderate-to-severe obstructive sleep apnea. (Note the interaction with Bridge rules: if you have moderate-to-severe OSA, you're routed to standard Part D, where that indication applies, rather than the Bridge.)

Side-effect profile is similar to other GLP-1-class drugs — gastrointestinal effects concentrated during dose escalation.

The KwikPen rule, in practice

Zepbound sells in several presentations: multi-dose KwikPens, single-dose pens, and vials with syringes. The Bridge covers the KwikPen only. What this means for you: ask your prescriber to specify KwikPen on the prescription, and if a pharmacy offers to substitute another form — or quotes you a price far above $50 — the form is the first thing to check. Lilly's vial pricing through LillyDirect is aimed at the self-pay market and is irrelevant (and more expensive) next to a $50 covered fill.

Take the 2-minute eligibility check →

Common questions

Why does the program cover only the KwikPen?

CMS specified the covered presentations in the program design. Whatever the rationale, the practical rule is absolute: KwikPen processes at $50; vials and single-dose pens don't process under the Bridge at all.

My pharmacy only stocks vials. What do I do?

Ask them to order the KwikPen or transfer the prescription to a pharmacy that stocks it — most chains can. Don't pay vial pricing out of pocket assuming it's covered; it isn't.

Is Zepbound stronger than Wegovy?

Head-to-head trial data showed greater average weight loss with tirzepatide, but 'better for you' depends on your cardiac history, tolerability, and prescriber judgment — both are covered at the same $50.

Related

Program-fact sources: CMS — Medicare GLP-1 Bridge · KFF